Although not approved for marketing in mainland China, the HPV vaccine has become a hot topic of discussion nowadays. The HPV vaccination program has now been introduced in Hong Kong and Macau, and as Guangdong is adjacent to Hong Kong and Macau, this is obviously a good news. To help more people have a more comprehensive and correct understanding of the HPV vaccine, this platform sends you the “9-valent, quadrivalent, bivalent HPV vaccine graphic comparison and frequently asked questions” so that we can popularize it, first of all, send the 9-valent, quadrivalent, bivalent HPV vaccine comparison chart: 1. The significance of HPV vaccination HPV infection is a systemic disease, cervical cancer, reproductive tract warts, vulvar cancer, penile cancer, laryngeal cancer, lung cancer, esophageal cancer, and anal cancer are all related to HPV infection. Of these diseases, cervical cancer and genital warts in particular are closely related to HPV, with 70% of cervical cancers caused by types 16 or 18 and 90% of genital warts (such as condyloma acuminata) caused by HPV types 6 or 11. Currently, vaccination is the most reliable means of preventing these diseases, and the efficiency of the vaccine in preventing CINII-III and vulvar warts caused by the corresponding HPV infection is close to 100% when the vaccination is completed according to the vaccination schedule. 2. The earliest age is 9 years old. If you are still not vaccinated at age 12, you can be vaccinated at age 13-26. Those who are 11-12 years old and not sexually active will have the best immunization results after vaccination. A woman’s previous history of CIN, VIN or genital warts does not affect vaccination. In Hong Kong, the upper age limit for vaccination can be up to 65 years. It should be noted that the United States is gradually promoting HPV vaccination as a basic immunization program, and some states have fully completed coverage, while Hong Kong and Macau have not yet reached this level, and the difference in health economics policies between the two regions is a possible reason for the difference in the age range of the vaccinated population. 3. Differences in the types of HPV vaccine efficacy, vaccination methods, and contraindications currently listed There are only three vaccines approved by the FDA, namely Cervarix (Huuyenkang, GlaxoSmithKline) and Gardasil4 and Gardasil9 (4-valent and 9-valent Gardasil vaccine, Merck). All three vaccines are inactivated vaccines with a capsid mechanism that does not contain viral DNA. Cervarix is a bivalent vaccine, targeting HPV types 16 and 18; Gardasil4 is a quadrivalent vaccine, targeting HPV types 16, 18, 11 and 6; Gardasil9 is a nine-valent vaccine, targeting HPV types 16, 18, 11 and 6 based on the addition of five new The vaccine covers the largest number of HPV virus types and can prevent 90% of HPV-related diseases and cancers for both men and women, but the bivalent vaccine can only be used for women. Both vaccines are equally effective in preventing HPV 16 and 18 HPV infections that cause related reproductive tract diseases (CIN, cervical cancer), and the quadrivalent and nine-valent vaccines also prevent reproductive tract warts due to HPV types 11 and 6 infections. All three vaccines are given in a 3-dose regimen as follows: ①Cervarix: Dose 1 – any time (0 months); Dose 2 – 1 month (1 month) after the first dose; Dose 3 – 6 months (6 months) after the first dose. ②Gardasil4: 1st injection – any time (0 month); 2nd injection – 2 months (February) after 1st injection; 3rd injection – 6 months (June) after 1st injection. (iii) Gardasil9: dose 1 – any time (0 months); dose 2 – 2 months after dose 1 (February); dose 3 – 6 months after dose 1 (June). All three vaccines are given intramuscularly, and immunization should be completed using the same vaccine as much as possible. Contraindications: Women who have been determined to be pregnant prior to vaccination and those who are allergic to protein yeast should not be vaccinated. 4. Safety of the vaccine and common adverse reactions The safety of the vaccine in the general population has been well established. As of the current location, more than 57,000,000 HPV vaccinations have been administered and no serious complications have been found to result from the use of the vaccine. Common adverse reactions following vaccination include mild pain, muscle tension, local edema, masses, localized skin redness, headache, fever, nausea, dizziness, and vomiting. Some patients experience syncope during vaccination; therefore, consider lying down for vaccination and staying for 15 minutes after injection. If patients show adverse reactions consistent with hypersensitivity reactions after vaccination, subsequent vaccination needs to be cautious or terminated. 5. Cross-reactivity between HPV vaccine and other vaccines At present, no cross-reactivity has been found between HPV vaccine and other vaccines, therefore, simultaneous vaccination does not conflict. 6. The effect of having sex before vaccination on vaccination Whether or not to receive HPV vaccine depends only on whether or not one belongs to the recommended population, therefore, a history of sexual life before vaccination does not affect vaccination, but the preventive effect of the vaccine will be significantly weakened after vaccination of these people. 7. Whether sexual intercourse is possible during vaccination Genital tract contact is the main but not the only way of HPV infection. Therefore, sexual intercourse is possible during vaccination, but contraception is recommended. 8. The need to test for HPV infection before vaccination HPV testing before vaccination is not recommended because: ① this practice does not bring any benefit to the patient; ② even if HPV infection is present, it does not affect the decision to vaccinate; ③ existing vaccines can prevent multiple HPV infections, and the possibility of a woman being infected with multiple HPV infections at the same time is extremely low. 9. Remedies for failure to follow the vaccination schedule There is no need to restart the vaccination for any missed dose, just continue to complete the follow-up vaccination. 10.Booster program The current three-dose vaccination program provides the most definite and effective immunization effect. What is the maximum duration of protection after vaccination? There is no clear answer to this question, but based on the available evidence, it is not recommended to increase the number of injections or the dose to boost the immune response. 11. Treatment of pregnancy during pregnancy, lactation or vaccination Both HPV vaccines are classified as Class B drugs in the FDA drug classification, and the HPV vaccine is an inactivated vaccine, which theoretically does not cause adverse effects on pregnancy. Although a medical record registry for vaccine use in pregnant women is in place, the safety of vaccination during pregnancy has not been fully evaluated. None of the four guidelines recommend testing women for pregnancy prior to vaccination, but contraception is still recommended during vaccination, and if pregnancy is detected subsequent vaccination should be discontinued until after delivery before continuing to complete the vaccination. HPV vaccination during breastfeeding is safe for both mother and child. 12.Therapeutic effect of HPV vaccine It is well established that HPV vaccine has no therapeutic effect on pre-existing lesions, such as CIN, cervical cancer and condyloma acuminata. 13. Cervical cancer screening after HPV vaccination The HPV vaccine cannot target all types of HPV. At present, it is still recommended that all vaccinated women receive formal screening according to the existing screening protocol, which is also the most important issue after vaccination.